JP2007525521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007525521A5 JP2007525521A5 JP2007501006A JP2007501006A JP2007525521A5 JP 2007525521 A5 JP2007525521 A5 JP 2007525521A5 JP 2007501006 A JP2007501006 A JP 2007501006A JP 2007501006 A JP2007501006 A JP 2007501006A JP 2007525521 A5 JP2007525521 A5 JP 2007525521A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- alkyl
- hcv
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 51
- 241000711549 Hepacivirus C Species 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 102000033147 ERVK-25 Human genes 0.000 claims 6
- 102000014150 Interferons Human genes 0.000 claims 6
- 108010050904 Interferons Proteins 0.000 claims 6
- 108091005771 Peptidases Proteins 0.000 claims 6
- 239000004365 Protease Substances 0.000 claims 6
- 229940079322 interferon Drugs 0.000 claims 6
- 239000003443 antiviral agent Substances 0.000 claims 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- -1 heteroalkenyl Chemical group 0.000 claims 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
- 229960000329 Ribavirin Drugs 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 230000000051 modifying Effects 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 108020005497 Nuclear hormone receptors Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000002730 additional Effects 0.000 claims 1
- 125000004946 alkenylalkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000005281 alkyl ureido group Chemical group 0.000 claims 1
- 125000005038 alkynylalkyl group Chemical group 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001747 exhibiting Effects 0.000 claims 1
- XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 101700032463 nhr-14 Proteins 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 1
- 238000003419 tautomerization reaction Methods 0.000 claims 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 C*(*)C(*)CN Chemical compound C*(*)C(*)CN 0.000 description 8
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54842304P | 2004-02-27 | 2004-02-27 | |
| PCT/US2005/006083 WO2005085197A1 (en) | 2004-02-27 | 2005-02-24 | Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007525521A JP2007525521A (ja) | 2007-09-06 |
| JP2007525521A5 true JP2007525521A5 (sl) | 2008-03-21 |
Family
ID=34919362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007501006A Pending JP2007525521A (ja) | 2004-02-27 | 2005-02-24 | Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしてのシクロブテンジオン基含有化合物 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1742914A1 (sl) |
| JP (1) | JP2007525521A (sl) |
| CN (1) | CN1946690A (sl) |
| CA (1) | CA2557301A1 (sl) |
| WO (1) | WO2005085197A1 (sl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060281689A1 (en) * | 2005-06-02 | 2006-12-14 | Schering Corporation | Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period |
| WO2006130687A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor |
| US20060275366A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
| US20060276407A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
| US20060276404A1 (en) * | 2005-06-02 | 2006-12-07 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
| CA2611145A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation useful for treating disorders associated with hepatitis c virus |
| US20060276406A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
| ES2443242T3 (es) | 2005-12-23 | 2014-02-18 | Zealand Pharma A/S | Compuestos modificados miméticos de lisina |
| US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| CN101506167A (zh) | 2006-08-17 | 2009-08-12 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
| PL2468724T3 (pl) | 2006-12-21 | 2016-05-31 | Zealand Pharma As | Synteza związków pirolidynowych |
| EP2188274A4 (en) | 2007-08-03 | 2011-05-25 | Boehringer Ingelheim Int | VIRAL POLYMERASE HEMMER |
| MX2010006313A (es) | 2007-12-19 | 2010-06-25 | Boehringer Ingelheim Int | Inhibidores de la polimerasa virica. |
| RU2011127080A (ru) | 2009-01-07 | 2013-02-20 | Сайнексис, Инк. | Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич |
| CN103387510B (zh) * | 2013-08-08 | 2015-09-09 | 苏州永健生物医药有限公司 | 一种β-氨基-alpha-羟基环丁基丁酰胺盐酸盐的合成方法 |
| EP3618847B1 (en) | 2017-05-05 | 2021-04-07 | Zealand Pharma A/S | Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168103A (en) * | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| PT1268519E (pt) * | 2000-04-03 | 2005-08-31 | Vertex Pharma | Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c |
| US7012066B2 (en) * | 2000-07-21 | 2006-03-14 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| CN1446201A (zh) * | 2000-07-21 | 2003-10-01 | 先灵公司 | 用作丙型肝炎病毒ns3－丝氨酸蛋白酶抑制剂的新型肽 |
| US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| CA2437400A1 (en) * | 2001-02-07 | 2002-08-15 | Abbott Laboratories | Aminal diones as potassium channel openers |
| MXPA03009441A (es) * | 2001-04-16 | 2004-02-12 | Schering Corp | Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc. |
| US20040106794A1 (en) * | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
-
2005
- 2005-02-24 WO PCT/US2005/006083 patent/WO2005085197A1/en active Application Filing
- 2005-02-24 CN CNA2005800126511A patent/CN1946690A/zh active Pending
- 2005-02-24 EP EP05723791A patent/EP1742914A1/en not_active Withdrawn
- 2005-02-24 CA CA002557301A patent/CA2557301A1/en not_active Abandoned
- 2005-02-24 JP JP2007501006A patent/JP2007525521A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007525521A5 (sl) | ||
| JP2007525510A5 (sl) | ||
| JP2007525514A5 (sl) | ||
| JP2007535496A5 (sl) | ||
| JP2007525512A5 (sl) | ||
| JP2007525518A5 (sl) | ||
| JP2008511633A5 (sl) | ||
| JP2004504404A5 (sl) | ||
| JP2005524628A5 (sl) | ||
| RU2404189C9 (ru) | Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита c | |
| RU2006124594A (ru) | Ингибиторы сериновой протеазы ns3/ns4а вируса гепатита с | |
| JP2005515255A5 (sl) | ||
| JP2004513881A5 (sl) | ||
| JP2007535491A5 (sl) | ||
| RU2006134002A (ru) | Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| RU2006134005A (ru) | Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| RU2006134003A (ru) | Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| JP2007515405A5 (sl) | ||
| RU2355700C2 (ru) | Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита с | |
| RU2006134000A (ru) | Новые кетоамиды с циклическим p4s, действующие как ингибиторы сериновой протеазы ns3 ируса гепатита с | |
| JP2007513971A5 (sl) | ||
| EP2368900A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| WO2004113365A3 (en) | Hepatitis c serine protease tri-peptide inhibitors | |
| JP2007532479A5 (sl) | ||
| JP2007534636A5 (sl) |